Inflation retreated in April, but tariffs are expected to re-ignite consumer prices in coming months.Read More

You might also be interested in reading Alnylam Pharmaceuticals sees $1.6B to $1.725B TTR revenue in 2025 driven by AMVUTTRA expansion.